Trial Profile
A retrospective study to assess the efficacy and safety of JAK inhibitors in the treatment of refractory systemic Juvenile idiopathic Arthritis (sJIA) or Adult and Childhood Onset Still'S Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jun 2021
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary) ; Ruxolitinib (Primary) ; Tofacitinib (Primary) ; Anakinra; Methotrexate; Steroids
- Indications Adult-onset Still's disease; Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- 22 Jun 2021 New trial record
- 05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism